MEDIPOST Clears Product Approval Renewal of CARTISTEM by the Ministry of Food and Drug Safety(MFDS)2019/03/26STEM CELL THERAPEUTIC
MEDIPOST, acquires a Japanese patent for the mesenchymal stem cell culture method2019/01/30STEM CELL THERAPEUTIC
MEDIPOST, ends phase I and II clinical trials with PNEUMOSTEM, the effective treatment of BPD for preterm infants2019/01/08STEM CELL THERAPEUTIC
MEDIPOST, signs a contract with SK Bioland for an ankle joint indication2019/01/02STEM CELL THERAPEUTIC
MEDIPOST acquires US Patent for the ‘Mesenchymal Stem Cell Culture Method’2018/10/24STEM CELL THERAPEUTIC
MEDIPOST acquires the Japanese patent in hair loss prevention and hair growth promoting composition2018/07/04STEM CELL THERAPEUTIC
MEDIPOST acquires patents on the “Mesenchymal Stem Cell Culture Method” in 6 European countries2018/06/27STEM CELL THERAPEUTIC
Significant increase in the revenue of MEDIPOST stem cell therapeutics CARTISTEM in comparison to the previous year2018/04/20STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for Stem Cell Culture Medium Technique for Hair Loss Treatment2018/02/28STEM CELL THERAPEUTIC
MEDIPOST’s Alzheimer’s Disease Drug Approved by FDA for Clinical Trials2018/02/05STEM CELL THERAPEUTIC
